AstraZeneca failed to win accelerated approval of a cancer drug in the U.S., dealing a blow to its new drug-development pipeline, a key plank of its defense in fighting off Pfizer's $120 billion takeover bid.
via WSJ.com: US Business http://ift.tt/1o5VawS
via WSJ.com: US Business http://ift.tt/1o5VawS
Nessun commento:
Posta un commento